OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Net Common Stock Issuance

Last Annual Value

5.23M

3-Year CAGR

%

5-Year CAGR

20%

10-Year CAGR

10%

OT

OS Therapies Incorporated Competitors Analysis of Net Common Stock Issuance

OSTX · NYSE
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.23M
N/AN/AN/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
46.40M
285.5%8.3%N/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
0.00
N/AN/AN/A
101.65M
80.0%5.3%N/A
30.79M
32.0%12.1%7.5%
9.55M
112.2%N/AN/A
6.03M
-31.0%-44.2%N/A
50.07M
-2.3%N/AN/A
12.97M
34.8%5.6%N/A
15.86M
25.0%-15.6%N/A
0.00
N/AN/AN/A
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42